(CercleFinance.com) – The American Medicines Agency announced Thursday that it had granted emergency authorization for the treatment against Covid-19 developed by Merck.
The FDA specifies that the green light concerns the use of molnupiravir in patients with mild or moderate forms of Covid at risk of progression to a severe form of the disease.
The health agency adds that the administration of molnupiravir has not been authorized in children under 18 because of its potential effects on the growth of bones and cartilage.
The product has not been approved, either, for the prevention of pre-exposure or post-exposure to the virus, underlines the FDA, which recalls that the drug of Merck does not constitute an alternative to the vaccination.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
